Fluvoxamine Market Size, Share & Growth Statistics Report to 2030

Fluvoxamine Market Size, Share, Growth Trends, Industry Analysis and Forecast to 2030

Report ID: RC129159 | Report Format: PDF + Excel | Last Updated: August 29th, 2025

The global fluvoxamine market size was valued at over USD 660 million in 2024 and projected to grow at a significant CAGR of over 3% during the forecast period 2025 to 2030. The rising prevalence of anxiety and depression across the globe is a major factor to drive the market growth. Moreover, the increasing incidence of social anxiety disorder is expected to propel the market growth over the forecast period. According to the latest report published, around 40 million people influence in the United States each year, and 8% of children and teenagers experience an anxiety disorder. According to WHO, 1 in 13 people experience anxiety disorder across the globe.

Report Attributes:

Benchmark Year		2024
Market Size		> USD 660 Million in 2024
Market Growth (CAGR)		3% (2025-2030)
Largest Market Share		North America
Analysis Period		2020-2030
Market Players		Apotex Corporation, Teva Pharmaceutical Industries Limited, Abbott Laboratories, Inc., and Others

Fluvoxamine Market Key Drivers:

The fluvoxamine market is primarily driven by the rising prevalence of mental health disorders, particularly depression, obsessive-compulsive disorder (OCD), and anxiety-related conditions. As one of the widely prescribed selective serotonin reuptake inhibitors (SSRIs), fluvoxamine is increasingly in demand due to its effectiveness in treating OCD and other psychiatric conditions where first-line treatments are required. Growing awareness of mental health, coupled with reducing social stigma and improved access to psychiatric care, is fueling higher diagnosis and treatment rates globally. In addition, the increasing burden of stress-related disorders driven by lifestyle changes, urbanization, and socioeconomic pressures continues to support the market’s growth.

Another key driving factor is the expansion of pharmaceutical distribution networks and healthcare infrastructure, particularly in emerging markets. Rising healthcare spending, coupled with favorable government initiatives for mental health treatment, is improving the availability and accessibility of fluvoxamine. Furthermore, ongoing research into the broader therapeutic potential of fluvoxamine, including its anti-inflammatory and immunomodulatory properties, has attracted attention during the COVID-19 pandemic, boosting awareness and demand. With a growing patient pool, supportive healthcare policies, and an increasing focus on psychiatric well-being, the fluvoxamine market is poised for sustained growth.

Industry Trends Shaping the Fluvoxamine Market:

The fluvoxamine market is witnessing a notable trend of increasing demand for psychiatric medications, driven by rising cases of depression, anxiety, and obsessive-compulsive disorder (OCD) worldwide. With mental health becoming a global priority, more patients are being diagnosed and treated, leading to higher prescriptions of SSRIs such as fluvoxamine. Additionally, telemedicine and digital health platforms are making psychiatric consultations more accessible, especially in remote areas, which in turn is boosting the uptake of fluvoxamine as part of prescribed treatment regimens.

Another key trend is the expansion of research into new therapeutic applications of fluvoxamine beyond mental health. During the COVID-19 pandemic, the drug gained attention for its potential anti-inflammatory and immunomodulatory effects, opening possibilities for its use in treating infectious or inflammatory conditions. While research is ongoing, this has expanded interest in the drug globally. Moreover, the pharmaceutical industry is seeing a rise in generic drug production, making fluvoxamine more affordable and widely available, particularly in developing regions. Combined with increasing investments in mental health awareness campaigns, these trends are shaping the future trajectory of the fluvoxamine market.

Fluvoxamine Market Opportunities:

The fluvoxamine market offers strong opportunities due to the growing global burden of mental health disorders and the increasing acceptance of psychiatric treatment. As depression, anxiety, and OCD cases continue to rise, there is significant potential for fluvoxamine to expand its patient base, especially in regions where awareness and diagnosis rates are improving. Emerging markets in Asia-Pacific, Latin America, and the Middle East present untapped opportunities as healthcare infrastructure strengthens and access to affordable psychiatric medications widens. The availability of fluvoxamine in generic form further enhances its adoption, making it accessible to a larger patient pool across both developed and developing economies.

Another major opportunity lies in the exploration of fluvoxamine’s therapeutic potential beyond psychiatric care. Research highlighting its anti-inflammatory and immunomodulatory properties has opened possibilities for its use in treating conditions such as long-COVID and other inflammatory disorders, potentially diversifying its application spectrum. Pharmaceutical companies investing in clinical trials and drug repurposing strategies could unlock new revenue streams and expand market presence. Additionally, partnerships with digital health platforms and telemedicine providers offer opportunities to reach a wider audience, ensuring greater prescription and adherence rates. Together, these factors create a favorable environment for long-term growth in the fluvoxamine market.

Market Segments Insights:

The global fluvoxamine market is bifurcated into clinical application, distribution channel, and geography. On the basis of clinical application, the market is further segmented into obsessive-compulsive disorder, post-traumatic disorder, and others. The obsessive-compulsive disorder segment held the largest market share and expected to maintain its dominance over the forecast period. According to the latest stats shared by NIH, around 2.3% of populations experience obsessive-compulsive disorder around the globe.

The fluvoxamine comprehensive study offers an in-depth analysis of industry trends, market size, competitive analysis, and market forecast – 2020 to 2027. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

Fluvoxamine Market Segmentation:

By Clinical Application:

Obsessive-Compulsive Disorder
Post Traumatic Stress Disorder
Others

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Others

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Geographic Coverage: North America Leads the Fluvoxamine Market

North America is currently dominating the geography segment for the fluvoxamine market. The rising prevalence of depression primarily drives the market growth in the region. As per the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately 2.3% of the United States population is reported to be suffering from obsessive-compulsive disorders.

Geographically, the fluvoxamine market report comprises dedicated sections centering on the regional market revenue and trends. The fluvoxamine market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, and Rest of the World (RoW). The RoW segment consists of Latin America and the Middle East & Africa. The market has been extensively analyzed on the basis of various regional factors such as demographics, gross domestic product (GDP), inflation rate, acceptance, and others. The market estimates have also been provided for the historical years along with forecasts for the period from 2025 – 2030.

Fluvoxamine Market Competition Assessment:

Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy. Key players operating in the global fluvoxamine market are Apotex Corporation, Teva Pharmaceutical Industries Limited, Abbott Laboratories, Inc., etc. together to propel the market growth in the region.

Key Companies:

Synthon BV.
Abbott Laboratories, Inc.
Merck KGaA
Sun Pharmaceuticals Ltd.
BayPharma GmbH
Apotex Corporation
Taiwan Biotech
Mylan Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited
Sandoz, Inc.

Key Questions Answered by Fluvoxamine Market Report:

Global fluvoxamine market forecasts from 2021-2027
Regional fluvoxamine market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
Fluvoxamine submarket forecasts from 2021-2027 covering the market by clinical application, by distribution channel, and geography
Various industry models such as SWOT analysis, Value Chain Analysis pertaining to the market
Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2021-2027
Competitive Landscape and market positioning of top 10 players operating in the market

Table of Content:

1. Preface

1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.4. Assumptions

2. Executive Summary

2.1. Global Fluvoxamine Market Portraiture
2.2. Global Fluvoxamine Market, by Clinical Application, 2020 (USD Mn)
2.3. Global Fluvoxamine Market, by Distribution Channel, 2020 (USD Mn)
2.4. Global Fluvoxamine Market, by Geography, 2020 (USD Mn)

3. Global Fluvoxamine Market Analysis

3.1. Fluvoxamine Market Overview
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Challenges
3.3.3. Opportunities
3.4. Attractive Investment Proposition
3.5. Competitive Analysis

4. Global Fluvoxamine Market By Clinical Application, 2018 – 2027 (USD Mn)

4.1. Overview
4.2. Hospital Pharmacy
4.3. Retail Pharmacy
4.4. Others

5. Global Fluvoxamine Market By Distribution Channel, 2018 – 2027 (USD Mn)

5.1. Overview
5.2. Obsessive-Compulsive Disorder
5.3. Post Traumatic Stress Disorder
5.4. Others

6. North America Fluvoxamine Market, By Geography, 2018 – 2027 (USD Mn)

6.1.1. Overview
6.1.2. North America Fluvoxamine Market by Clinical Application (2018-2027 USD Mn)
6.1.3. North America Fluvoxamine Market by Distribution Channel (2018-2027 USD Mn)
6.1.4. North America Fluvoxamine Market by Country (2018-2027 USD Mn)
6.1.4.1. U.S.
6.1.4.2. Canada

7. Europe Fluvoxamine Market, By Geography, 2018 – 2027 (USD Mn)

7.1.1. Overview
7.1.2. Europe Fluvoxamine Market by Clinical Application (2018-2027 USD Mn)
7.1.3. Europe Fluvoxamine Market by Distribution Channel (2018-2027 USD Mn)
7.1.4. Europe Fluvoxamine Market by Country (2018-2027 USD Mn)
7.1.4.1. Germany
7.1.4.2. U.K.
7.1.4.3. France
7.1.4.4. Italy
7.1.4.5. Rest of Europe

8. Asia Pacific Fluvoxamine Market, By Geography, 2018 – 2027 (USD Mn)

8.1.1. Overview
8.1.2. Asia Pacific Fluvoxamine Market by Clinical Application (2018-2027 USD Mn)
8.1.3. Asia Pacific Fluvoxamine Market by Distribution Channel (2018-2027 USD Mn)
8.1.4. Asia Pacific Fluvoxamine Market by Country (2018-2027 USD Mn)
8.1.4.1. China.
8.1.4.2. Japan
8.1.4.3. Rest of Asia Pacific

9. Latin America (LATAM) Fluvoxamine Market, By Geography, 2018 – 2027 (USD Mn)

9.1.1. Overview
9.1.2. Latin America Fluvoxamine Market by Clinical Application (2018-2027 USD Mn)
9.1.3. Latin America Fluvoxamine Market by Distribution Channel (2018-2027 USD Mn)
9.1.4. Latin America Fluvoxamine Market by Country (2018-2027 USD Mn)
9.1.4.1. Brazil
9.1.4.2. Mexico
9.1.4.3. Rest of Latin America

10. Middle East and Africa Fluvoxamine Market, By Geography, 2018 – 2027 (USD Mn)

10.1.1. Overview
10.1.2. MEA Fluvoxamine Market by Clinical Application (2018-2027 USD Mn)
10.1.3. MEA Fluvoxamine Market by Distribution Channel (2018-2027 USD Mn)
10.1.4. Middle East and Africa Fluvoxamine Market, by Country (2018-2027 USD Mn)
10.1.4.1. GCC
10.1.4.2. Rest of MEA

11. Company Profiles

11.1. Synthon BV.
11.1.1. Business Description
11.1.2. Financial Health and Budget Allocation
11.1.3. Product Positions/Portfolio
11.1.4. Recent Development
11.1.5. SWOT Analysis
11.2. Abbott Laboratories, Inc.
11.2.1. Business Description
11.2.2. Financial Health and Budget Allocation
11.2.3. Product Positions/Portfolio
11.2.4. Recent Development
11.2.5. SWOT Analysis
11.3. Merck KGaA
11.3.1. Business Description
11.3.2. Financial Health and Budget Allocation
11.3.3. Product Positions/Portfolio
11.3.4. Recent Development
11.3.5. SWOT Analysis
11.4. Sun Pharmaceuticals Ltd.
11.4.1. Business Description
11.4.2. Financial Health and Budget Allocation
11.4.3. Product Positions/Portfolio
11.4.4. Recent Development
11.4.5. SWOT Analysis
11.5. BayPharma GmbH
11.5.1. Business Description
11.5.2. Financial Health and Budget Allocation
11.5.3. Product Positions/Portfolio
11.5.4. Recent Development
11.5.5. SWOT Analysis
11.6. Apotex Corporation
11.6.1. Business Description
11.6.2. Financial Health and Budget Allocation
11.6.3. Product Positions/Portfolio
11.6.4. Recent Development
11.6.5. SWOT Analysis
11.7. Taiwan Biotech
11.7.1. Business Description
11.7.2. Financial Health and Budget Allocation
11.7.3. Product Positions/Portfolio
11.7.4. Recent Development
11.7.5. SWOT Analysis
11.8. Mylan Pharmaceutical Industries Limited
11.8.1. Business Description
11.8.2. Financial Health and Budget Allocation
11.8.3. Product Positions/Portfolio
11.8.4. Recent Development
11.8.5. SWOT Analysis
11.9. Teva Pharmaceutical Industries Limited
11.9.1. Business Description
11.9.2. Financial Health and Budget Allocation
11.9.3. Product Positions/Portfolio
11.9.4. Recent Development
11.9.5. SWOT Analysis
11.10. Sandoz, Inc.
11.10.1. Business Description
11.10.2. Financial Health and Budget Allocation
11.10.3. Product Positions/Portfolio
11.10.4. Recent Development
11.10.5. SWOT Analysis

To know more about the study, request a full report sample

List of Tables:

TABLE 1 Market Snapshot: Global Fluvoxamine Market

TABLE 2 Impact Indicators

TABLE 3 Impact Analysis of Drivers and Challenges

TABLE 4 Global Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 5 Global Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 6 North America Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 7 North America Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 8 North America Fluvoxamine Market Value, By Country, 2018 - 2027 (US$ Mn)

TABLE 9 U.S. Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 10 U.S. Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 11 Canada Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 12 Canada Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 13 Europe Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 14 Europe Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 15 Europe Fluvoxamine Market Value, by Country, 2018 - 2027 (US$ Mn)

TABLE 16 Germany Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 17 Germany Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 18 U.K. Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 19 U.K. Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 20 France Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 21 France Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 22 Italy Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 23 Italy Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 24 Rest of Europe Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 25 Rest of Europe Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 26 Asia Pacific Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 27 Asia Pacific Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 28 Asia Pacific Fluvoxamine Market Value, by Country, 2018 - 2027 (US$ Mn)

TABLE 29 Japan Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 30 Japan Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 31 China Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 32 China Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 33 Rest of Asia Pacific Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 34 Rest of Asia Pacific Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 35 Latin America Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 36 Latin America Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 37 Latin America Fluvoxamine Market Value, by Country, 2018 - 2027 (US$ Mn)

TABLE 38 Brazil Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 39 Brazil Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 40 Mexico Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 41 Mexico Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 42 Rest of Latin America Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 43 Rest of Latin America Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 44 Middle East & Africa Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 45 Middle East & Africa Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 46 Middle East & Africa Fluvoxamine Market Value, by Country, 2018 - 2027 (US$ Mn)

TABLE 47 GCC Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 48 GCC Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 49 Rest of MEA Fluvoxamine Market Value, by Clinical Application, 2018 - 2027 (US$ Mn)

TABLE 50 Rest of MEA Fluvoxamine Market Value, by Distribution Channel, 2018 - 2027 (US$ Mn)

TABLE 51 Synthon BV.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 52 Abbott Laboratories, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 53 Merck KGaA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 54 Sun Pharmaceuticals Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 55 BayPharma GmbH: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 56 Apotex Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 57 Taiwan Biotech: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 58 Mylan Pharmaceutical Industries Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 59 Teva Pharmaceutical Industries Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

TABLE 60 Sandoz, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent Developments)

To know more about the study, request a full report sample

List of Figures:

FIG. 1 Global Fluvoxamine: Market Segmentation

FIG. 2 Global Fluvoxamine Market: Research Methodology

FIG. 3 Top-Down and Bottom-up Approach

FIG. 4 Global Fluvoxamine Market, by Clinical Application, 2019 (US$ Mn)

FIG. 5 Global Fluvoxamine Market, by Distribution Channel, 2019 (US$ Mn)

FIG. 6 Global Fluvoxamine Market, by Geography, 2019 (US$ Mn)

FIG. 7 Global Fluvoxamine Market Value and Growth, 2018 – 2027, (US$ Mn) (Y-o-Y %)

FIG. 8 Attractive Investment Proposition, by Geography, 2017

FIG. 9 Market Positioning of Key Fluvoxamine Providers, 2019

FIG. 10 Global Fluvoxamine Market Value Share, by Clinical Application, 2018 & 2027 (%)

FIG. 11 Global Fluvoxamine Market Value for Obsessive-Compulsive Disorder, 2018 - 2027, (US$ Mn)

FIG. 12 Global Fluvoxamine Market Value for Post Traumatic Stress Disorder, 2018 - 2027, (US$ Mn)

FIG. 13 Global Fluvoxamine Market Value for Others, 2018 - 2027, (US$ Mn)

FIG. 14 Global Fluvoxamine Market Value Share, by Distribution Channel, 2018 & 2027 (Value %)

FIG. 15 Global Fluvoxamine Market Value for Hospital Pharmacy, 2018 - 2027, (US$ Mn)

FIG. 16 Global Fluvoxamine Market Value for Retail Pharmacy, 2018 - 2027, (US$ Mn)

FIG. 17 Global Fluvoxamine Market Value for Others, 2018 - 2027, (US$ Mn)

FIG. 18 North America Fluvoxamine Market Value, 2018 - 2027, (US$ Mn)

FIG. 19 Europe Fluvoxamine Market Value, 2018 - 2027, (US$ Mn)

FIG. 20 Asia Pacific Fluvoxamine Market Value, 2018 - 2027, (US$ Mn)

FIG. 21 LATIN America Fluvoxamine Market Value, 2018 - 2027, (US$ Mn)

FIG. 22 Middle East & Africa Fluvoxamine Market Value, 2018 - 2027, (US$ Mn)

Fill the given form to inquiry before buying for Fluvoxamine Market Report

Download Sample Papers

Inquiry Before Buying

Schedule a Call

Select License Type

$ 4250/- Single User License
$ 5200/- Multi User License
$ 6950/- Corporate License